These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 24851237

  • 1. Blockade of glutamate release by botulinum neurotoxin type A in humans: a dermal microdialysis study.
    Bittencourt da Silva L, Karshenas A, Bach FW, Rasmussen S, Arendt-Nielsen L, Gazerani P.
    Pain Res Manag; 2014; 19(3):126-32. PubMed ID: 24851237
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis.
    Gazerani P, Au S, Dong X, Kumar U, Arendt-Nielsen L, Cairns BE.
    Pain; 2010 Dec; 151(3):606-616. PubMed ID: 20728992
    [Abstract] [Full Text] [Related]

  • 4. Botulinum neurotoxin type A modulates vesicular release of glutamate from satellite glial cells.
    da Silva LB, Poulsen JN, Arendt-Nielsen L, Gazerani P.
    J Cell Mol Med; 2015 Aug; 19(8):1900-9. PubMed ID: 25754332
    [Abstract] [Full Text] [Related]

  • 5. The effect of botulinum neurotoxin-A on blood flow in rats: a potential mechanism for treatment of Raynaud phenomenon.
    Stone AV, Koman LA, Callahan MF, Eckman DM, Smith BP, Plate JF, Smith TL.
    J Hand Surg Am; 2012 Apr; 37(4):795-802. PubMed ID: 22386546
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cutaneous interstitial nitric oxide concentration does not increase during heat stress in humans.
    Crandall CG, MacLean DA.
    J Appl Physiol (1985); 2001 Mar; 90(3):1020-4. PubMed ID: 11181614
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder.
    Ikeda Y, Zabbarova IV, Birder LA, de Groat WC, McCarthy CJ, Hanna-Mitchell AT, Kanai AJ.
    Eur Urol; 2012 Dec; 62(6):1157-64. PubMed ID: 22480459
    [Abstract] [Full Text] [Related]

  • 10. Botulinum toxin type A on cutaneous flap viability in diabetic and tobacco-exposed rats.
    Camargo CP, Jacomo AL, Battlehner CN, Lemos M, Saldiva PH, Martins MA, Munhoz AM, Gemperli R.
    Acta Cir Bras; 2015 Sep; 30(9):639-45. PubMed ID: 26465109
    [Abstract] [Full Text] [Related]

  • 11. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin.
    Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L.
    Pain; 2009 Jan; 141(1-2):60-9. PubMed ID: 19004549
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Serotonin, glutamate and glycerol are released after the injection of hypertonic saline into human masseter muscles - a microdialysis study.
    Louca S, Christidis N, Ghafouri B, Gerdle B, Svensson P, List T, Ernberg M.
    J Headache Pain; 2014 Dec 17; 15(1):89. PubMed ID: 25519464
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Rubin M, Dover J, Maas C, Nestor M.
    Aesthet Surg J; 2009 Nov 17; 29(6 Suppl):S50-6. PubMed ID: 19945005
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.